The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy

Barbieri, Elisa; Porcu, Gloria; Petigara, Tanaz; Senese, Francesca; Prandi, Gian Marco; Scamarcia, Antonio; Cantarutti, Luigi; Cantarutti, Anna; Giaquinto, Carlo

doi:10.3390/children9091347

Cited by 4 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2011, a study on the risk of hospitalization due to pneumococcal disease in Spain [20] reflected a direct economic burden of PP of EUR 47 million, with EUR 57 million accounting for all invasive pneumococcal disease. This is consistent with the data offered by another study in 2015 on the impact of four vaccine-preventable diseases in older adults in Spain [5] and Italy, where, despite reductions in pneumococcal disease-related expenditures following the introduction of PCV13, there continues to be an important economic burden associated with pneumococcal disease [21]. In Norway, a recent study indicated that the burden of noninvasive pneumococcal pneumonia hospitalization had a substantial impact on the health and health care use of the 50+ population in Norway, despite the childhood immunization program [22].…”

Section: Discussionsupporting

confidence: 91%

Burden of Hospitalizations Related to Pneumococcal Infection in Spain (2016–2020)

et al. 2023

View full text Add to dashboard Cite

Pneumococcal infection strongly contributes to morbidity and mortality in Spain. A total of 253,899 hospitalizations related to pneumococcal infection occurred from 2016 to 2020. Fifty-eight percent were men, the mean age was 67 years old, and the average length of hospitalization was 12.72 days. The annual hospitalization rate was 10.84 hospitalizations per 10,000 population, increasing significantly with age, reaching 65.75 per 10,000 population in those aged >85 years. The hospitalization rates for pneumococcal pneumonia, sepsis, and meningitis were 2.91, 0.12, and 0.08 hospitalizations per 10,000, respectively, and reached the highest value in those aged >85 for pneumococcal pneumonia and sepsis, with 22.29 and 0.71 hospitalizations per 10,000, respectively, and in children up to 1 year old for pneumococcal meningitis, with 0.33 hospitalizations per 10,000. The total number of deaths during the study period was 35,716, with a case-fatality rate of 14.07%. For pneumococcal pneumonia, sepsis, and meningitis, the case-fatality rates were 8.47%, 23.71%, and 9.99%, respectively. The case-fatality rate increased with age and did not vary by sex. The annual cost of these hospitalizations was more than EUR 359 million. There is therefore a high burden of disease and mortality caused by pneumococcal infection in our country, especially in elderly individuals.

show abstract

Section: Discussionsupporting

confidence: 91%

Burden of Hospitalizations Related to Pneumococcal Infection in Spain (2016–2020)

et al. 2023

View full text Add to dashboard Cite

show abstract

The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years (2020–2070)

Lang,

Samant,

Cook

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Italy implemented two-dose universal varicella vaccination (UVV) regionally from 2003 to 2013 and nationally from 2017 onwards. Our objective was to analyze regional disparities in varicella outcomes resulting from disparities in vaccine coverage rates (VCRs) projected over a 50-year time-horizon (2020–2070). A previously published dynamic transmission model was updated to quantify the potential public health impact of the UVV program in Italy at the national and regional levels. Four 2-dose vaccine strategies utilizing monovalent (V) and quadrivalent (MMRV) vaccines were evaluated for each region: (A) MMRV-MSD/MMRV-MSD, (B) MMRV-GSK/MMRV-GSK, (C) V-MSD/MMRV-MSD, and (D) V-GSK/MMRV-GSK. Costs were reported in 2022 Euros. Costs and quality-adjusted life-years (QALYs) were discounted 3% annually. Under strategy A, the three regions with the lowest first-dose VCR reported increased varicella cases (+ 34.3%), hospitalizations (+ 20.0%), QALYs lost (+ 5.9%), payer costs (+ 22.2%), and societal costs (+ 14.6%) over the 50-year time-horizon compared to the three regions with highest first-dose VCR. Regions with low first-dose VCR were more sensitive to changes in VCR than high first-dose VCR regions. Results with respect to second-dose VCR were qualitatively similar, although smaller in magnitude. Results were similar across all vaccine strategies.

show abstract

Public health impact and return on investment of the pediatric National Immunization Program in Italy

Barbieri,

Talbird,

Carrico

et al. 2024

Expert Review of Vaccines

View full text Add to dashboard Cite

The Economic Burden of Pneumococcal Disease in Children: A Population-Based Investigation in the Veneto Region of Italy

Cited by 4 publications

References 18 publications

Burden of Hospitalizations Related to Pneumococcal Infection in Spain (2016–2020)

Burden of Hospitalizations Related to Pneumococcal Infection in Spain (2016–2020)

The clinical and economic costs associated with regional disparities in varicella vaccine coverage in Italy over 50 years (2020–2070)

Public health impact and return on investment of the pediatric National Immunization Program in Italy

Contact Info

Product

Resources

About